$CRDF

PACE GARY W purchased $1,000K of CRDF

PACE GARY W purchased 687,285 shares of Cardiff Oncology, Inc. (CRDF) at $1.46 ($1.00M total) on 2026-07-14.

Original reporting
SEC EDGAR · PACE GARY W
Published Jul 16, 2026, 8:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CRDF
Bullish
medium confidence
Mentioned
$CRDF
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRDFBullishLow
01

Why it matters

Insider buying may modestly support sentiment, but without accompanying operational updates it is unlikely to change valuation drivers.

02

Market read

Traders may monitor CRDF for sentiment follow-through, but the filing alone does not provide new fundamental information.

03

What to watch

The article lacks context on prior insider activity, total insider ownership changes beyond the post-transaction figure, and whether the purchase was funded by liquidity events.

Relevance 6/10Novelty 4/10Timing: after-hours filing date, 2026-07-16 (transaction dated 2026-07-14)

Background

The article is an SEC Form 4 insider transaction disclosure for Cardiff Oncology, Inc.

Company-level read

Ticker impact

$CRDFBullishMedium confidence
Context

Cardiff Oncology director PACE GARY W filed a Form 4 open-market purchase of 687,285 shares at $1.4550 on 2026-07-14.

Expected impact

Near-term impact is likely limited; any reaction would be sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

This is a primary-source insider transaction with a large share count and near-$1.46 price, but the text provides no new company performance or forward-looking information.

Market effects

No direct sector read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine or planned; the filing notes no 10b5-1 plan, but it still does not confirm conviction or timing advantage.

Key entities

  • Cardiff Oncology, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • PACE GARY W

    Director who purchased 687,285 shares open-market at $1.4550 on 2026-07-14.

Related articles

$CRDFMedAI 8/10

Cardiff Oncology Announces $10 Million Registered Direct Offering

Cardiff Oncology (Nasdaq: CRDF) announced a $10 million registered direct offering. It will sell 8,571,429 common shares with warrants at $1.05 per share, plus insider participation of 731,707 shares at $1.435 per share. Warrants exercise at $1.31, exercisable after six months and stockholder-authorized share increase. Closing expected July 16, 2026.